Physician profile
Corrine E Blum
NPI 1013321074
$3,552.73
in general payments reported to CMS, 2019-2025
16 companies · $989 in 2025
The $989 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $78.53 · 2021: $501 · 2022: $631 · 2023: $383 · 2024: $564 · 2025: $989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,687 · Honoraria: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,686.60 |
| Honoraria | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $663.69 | 2020-2025 | Precision7, Total30, Precision 1 |
| Coopervision INC. | $609.01 | 2021-2025 | Myday Contact Lens, Paragon Crt, Misight Contact Lens |
| Visioneering Technologies, INC. | $392.68 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $330.12 | 2019-2020 | |
| Lkc Technologies, INC. | $272.62 | 2024-2025 | |
| Abbvie INC. | $249.20 | 2022-2025 | |
| Glaukos Corporation | $244.62 | 2022 | |
| Topcon Healthcare, INC. | $215.30 | 2024 | |
| Kala Pharmaceuticals, INC. | $137.51 | 2021 | |
| Rxsight INC | $124.43 | 2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge |
| Eyevance Pharmaceuticals LLC | $121.80 | 2021 | |
| Sun Pharmaceutical Industries INC. | $79.00 | 2023-2025 | Cequa |
| Allergan, INC. | $39.96 | 2021 | |
| Bausch & Lomb Americas INC. | $37.18 | 2025 | Miebo, Xiidra |
| Biotissue Holdings INC. | $18.07 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $17.54 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corrine Blum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.